Danshen injection ameliorates STZ-induced diabetic nephropathy in association with suppression of oxidative stress, pro-inflammatory factors and fibrosis

International Immunopharmacology

Volumn 38, Issue , 2016, Pages 385-394

  Xu, Linhao ^a   Shen, Peiqiang ^b   Bi, Yanli ^c   Chen, Jian ^a   Xiao, Zhangang ^d   Zhang, Xiaoming ^a   Wang, Zheng ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Research and Development Center of Chiatai Qingchunbao   (China)

^c Hangzhou Hai Qin Sanatorium ^*  (China)

^d SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

Danshen injection; Diabetic nephropathy; Inflammation; Oxidative stress; Renal function

Indexed keywords

COLLAGEN; CREATININE; DANSHEN INJECTION; FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MALONALDEHYDE; NITROGEN; PROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; SALVIA MILTIORRHIZA EXTRACT; SMAD PROTEIN; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UREA; ANTIINFLAMMATORY AGENT; AUTACOID; CYTOKINE; PLANT EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; EXPERIMENTAL DIABETIC NEPHROPATHY; GENE REPRESSION; LOW DRUG DOSE; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZATION; RAT; RENAL PROTECTION; SALVIA MILTIORRHIZA; SIGNAL TRANSDUCTION; UREA NITROGEN BLOOD LEVEL; ANIMAL; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUG EFFECTS; FIBROSIS; IMMUNOLOGY; KIDNEY; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CREATININE; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBROSIS; INFLAMMATION MEDIATORS; KIDNEY; MALE; NF-KAPPA B; OXIDATIVE STRESS; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; SALVIA MILTIORRHIZA; SIGNAL TRANSDUCTION; SMAD PROTEINS; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84976287162     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2016.06.024     Document Type: Article

References (39)

1. [1] van Dijk, C., Berl, T., Pathogenesis of diabetic nephropathy. Rev. Endocr. Metab. Disord. 5 (2004), 237–248.
2. [2] Mariappan, M.M., Signaling mechanisms in the regulation of renal matrix metabolism in diabetes. Exp. Diabetes Res., 2012, 2012, 749812.
3. [3] Tan, A.L., Forbes, J.M., Cooper, M.E., AGE, RAGE, and ROS in diabetic nephropathy. Semin. Nephrol. 27 (2007), 130–143.
4. [4] Stieger, N., Worthmann, K., Teng, B., Engeli, S., Das, A.M., Haller, H., et al. Impact of high glucose and transforming growth factor-beta on bioenergetic profiles in podocytes. Metabolism 61 (2012), 1073–1086.
5. [5] Lee, G.T., Ha, H., Jung, M., Li, H., Hong, S.W., Cha, B.S., et al. Delayed treatment with lithospermate B attenuates experimental diabetic renal injury. J. Am. Soc. Nephrol. 14 (2003), 709–720.
6. [6] Navarro-Gonzalez, J.F., Mora-Fernandez, C., Muros de Fuentes, M., Garcia-Perez, J., Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat. Rev. Nephrol. 7 (2011), 327–340.
7. [7] Kanwar, Y.S., Sun, L., Xie, P., Liu, F.Y., Chen, S., A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu. Rev. Pathol. 6 (2011), 395–423.
8. [8] Lim, A.K., Tesch, G.H., Inflammation in diabetic nephropathy. Mediat. Inflamm., 2012, 2012, 146154.
9. [9] Schmid, H., Boucherot, A., Yasuda, Y., Henger, A., Brunner, B., Eichinger, F., et al. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55 (2006), 2993–3003.
10. [10] He, X., Young, S.H., Schwegler-Berry, D., Chisholm, W.P., Fernback, J.E., Ma, Q., Multiwalled carbon nanotubes induce a fibrogenic response by stimulating reactive oxygen species production, activating NF-kappaB signaling, and promoting fibroblast-to-myofibroblast transformation. Chem. Res. Toxicol. 24 (2011), 2237–2248.
11. [11] Lan, H.Y., Transforming growth factor-beta/Smad signalling in diabetic nephropathy. Clin. Exp. Pharmacol. Physiol. 39 (2012), 731–738.
12. [12] Zhang, J.L., Cui, M., He, Y., Yu, H.L., Guo, D.A., Chemical fingerprint and metabolic fingerprint analysis of Danshen injection by HPLC-UV and HPLC-MS methods. J. Pharm. Biomed. Anal. 36 (2005), 1029–1035.
13. [13] Zhao, D., Han, D.E., Li, N., Lu, Y., Li, T.T., Yang, S.Y., et al. Simultaneous determination of six phenolic constituents of Danshen injection in rat plasma by LC-ESI-MS and its application to a pharmacokinetic study. Eur. J. Mass Spectrom. (Chichester, Eng) 17 (2011), 395–403.
14. [14] Zhang, Y., Wang, H., Cui, L., Liu, Y., Chu, X., Liu, Z., et al. Continuing treatment with Salvia miltiorrhiza injection attenuates myocardial fibrosis in chronic iron-overloaded mice. PLoS One, 10, 2015, e0124061.
15. [15] Chan, K., Chui, S.H., Wong, D.Y., Ha, W.Y., Chan, C.L., Wong, R.N., Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction. Life Sci. 75 (2004), 3157–3171.
16. [16] Wang, M.X., Liu, Y.Y., Hu, B.H., Wei, X.H., Chang, X., Sun, K., et al. Total salvianolic acid improves ischemia-reperfusion-induced microcirculatory disturbance in rat mesentery. World J. Gastroenterol. 16 (2010), 5306–5316.
17. [17] Yin, D., Yin, J., Yang, Y., Chen, S., Gao, X., Renoprotection of Danshen injection on streptozotocin-induced diabetic rats, associated with tubular function and structure. J. Ethnopharmacol. 151 (2014), 667–674.
18. [18] Kim, J.S., Narula, A.S., Jobin, C., Salvia miltiorrhiza water-soluble extract, but not its constituent salvianolic acid B, abrogates LPS-induced NF-kappaB signalling in intestinal epithelial cells. Clin. Exp. Immunol. 141 (2005), 288–297.
19. [19] Li, M., Zhang, L., Cai, R.L., Gao, Y., Qi, Y., Lipid-soluble extracts from Salvia miltiorrhiza inhibit production of LPS-induced inflammatory mediators via NF-kappaB modulation in RAW 264.7 cells and perform antiinflammatory effects in vivo. Phytother. Res. 26 (2012), 1195–1204.
20. [20] Zhou, L., Zuo, Z., Chow, M.S., Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol. 45 (2005), 1345–1359.
21. [21] Ziyadeh, F.N., Wolf, G., Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr. Diabetes Rev. 4 (2008), 39–45.
22. [22] Wang, Y., Luo, M., Wu, H., Kong, L., Xin, Y., Cui, W., et al. Novel curcumin analog C66 prevents diabetic nephropathy via JNK pathway with the involvement of p300/CBP-mediated histone acetylation. Biochim. Biophys. Acta 2015 (1852), 34–46.
23. [23] Zhao, T.T., Zhang, H.J., Lu, X.G., Huang, X.R., Zhang, W.K., Wang, H., et al. Chaihuang-Yishen granule inhibits diabetic kidney disease in rats through blocking TGF-beta/Smad3 signaling. PLoS One, 9, 2014, e90807.
24. [24] Xu, F., Wang, Y., Cui, W., Yuan, H., Sun, J., Wu, M., et al. Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: possible roles of Akt/NF-kappaB pathway. Int. J. Endocrinol., 2014, 2014, 289327.
25. [25] Lee, H.S., Ku, S.K., Effect of Picrorrhiza rhizoma extracts on early diabetic nephropathy in streptozotocin-induced diabetic rats. J. Med. Food 11 (2008), 294–301.
26. [26] Karasu, C., Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment. Open Cardiovasc. Med. J. 4 (2010), 240–256.
27. [27] Korish, A.A., Abdel Gader, A.G., Korashy, H.M., Al-Drees, A.M., Alhaider, A.A., Arafah, M.M., Camel milk attenuates the biochemical and morphological features of diabetic nephropathy: inhibition of Smad1 and collagen type IV synthesis. Chem. Biol. Interact. 229 (2015), 100–108.
28. [28] Craven, P.A., Melhem, M.F., Phillips, S.L., DeRubertis, F.R., Overexpression of Cu2 +/Zn2 + superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 50 (2001), 2114–2125.
29. [29] Taniyama, Y., Griendling, K.K., Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42 (2003), 1075–1081.
30. [30] Anrather, J., Racchumi, G., Iadecola, C., NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J. Biol. Chem. 281 (2006), 5657–5667.
31. [31] Li, Q., Verma, I.M., NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2 (2002), 725–734.
32. [32] Rajendrasozhan, S., Yang, S.R., Edirisinghe, I., Yao, H., Adenuga, D., Rahman, I., Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid. Redox Signal. 10 (2008), 799–811.
33. [33] Garcia-Cenador, M.B., Lorenzo-Gomez, M.F., Herrero-Payo, J.J., Ruiz, J., Perez de Obanos, M.P., Pascual, J., et al. Cardiotrophin-1 administration protects from ischemia-reperfusion renal injury and inflammation. Transplantation 96 (2013), 1034–1042.
34. [34] Wu, C.C., Sytwu, H.K., Lin, Y.F., Cytokines in diabetic nephropathy. Adv. Clin. Chem. 56 (2012), 55–74.
35. [35] Aksu, U., Guner, I., Yaman, O.M., Erman, H., Uzun, D., Sengezer-Inceli, M., et al. Fluoxetine ameliorates imbalance of redox homeostasis and inflammation in an acute kidney injury model. J. Physiol. Biochem. 70 (2014), 925–934.
36. [36] Erensoy, N., Yilmazer, S., Ozturk, M., Tuncdemir, M., Uysal, O., Hatemi, H., Effects of ACE inhibition on the expression of type IV collagen and laminin in renal glomeruli in experimental diabetes. Acta Histochem. 106 (2004), 279–287.
37. [37] He, K., Li, X., Chen, X., Ye, X., Huang, J., Jin, Y., et al. Evaluation of antidiabetic potential of selected traditional Chinese medicines in STZ-induced diabetic mice. J. Ethnopharmacol. 137 (2011), 1135–1142.
38. [38] Zhai, Y.P., Lu, Q., Liu, Y.W., Cheng, Q., Wei, Y.Q., Zhang, F., et al. Over-production of nitric oxide by oxidative stress-induced activation of the TGF-beta1/PI3K/Akt pathway in mesangial cells cultured in high glucose. Acta Pharmacol. Sin. 34 (2013), 507–514.
39. [39] Ha, H., Yu, M.R., Lee, H.B., High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int. 59 (2001), 463–470.